[The Bell] Synthesis Biotech prepares management innovation committee, 'strengthening internal controls'
Predicted impact: Low
Management innovation committee plan already reported recently; internal governance step
Synteka Bio신테카바이오
226330 · KOSDAQ · ₩226330 · 신테카바이오
₩1,059▼ ₩15 (1.40%)End-of-day · Oct 29, 2026 · End-of-day prices.
Price · 1Y −66.78%
- Market cap
- ₩26B
- Enterprise value
- ₩25B
- P/E
- —
- P/B
- 1.0×
- Dividend yield
- 0.0%
- ROE
- −46.3%
- Net margin
- −389.1%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−84.3% from the high
₩976Today: ₩1,000 – ₩1,110₩6,750
Returns
- 1W+4.5%
- 1M−20.6%
- 3M−23.0%
- 6M−66.6%
- YTD−72.8%
- 1Y−66.8%
- Volume today
- 79,242
- 0.4× the 20-day average
- Traded today
- ₩83M
- Listed shares
- 24,258,475
- EPS (12 months)
- −₩495
- Earnings yield −46.7%
AI researchResearch being writtenOur AI is writing a report on this company from filed data, prices and news. Check back soon.
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 29 of 100 (50 is a normal day for this stock).
- MomentumWeak-20.1% over the last month; the price is below its 20-day average.
- News impactSome4 news items and filings in two weeks; 0 rated high impact, 1 medium.
Signals describe activity, not recommendations. Not financial advice.
Synteka Bio stock overview
Synteka Bio (신테카바이오, KRX: 226330) is listed on KOSDAQ, in the Software sector. Shinteka Bio is a Korean biotech venture founded in 2009 that develops AI drug discovery platforms built on three-dimensional protein structure and genomic big data. Its shares closed at ₩1,059 on Oct 29, 2026, down 1.40% on the day, giving it a market value of ₩26B.
Key facts
- Market cap
- ₩26B
- Sector
- Software
- Latest price change
- −1.40%
- As of
- Oct 29, 2026
- Main business
- Shinteka Bio is a Korean biotech venture founded in 2009 that develops AI drug discovery platforms built on three-dimensional protein structure and genomic big data.
Quick answers about Synteka Bio
- What does Synteka Bio do?
- Shinteka Bio is a Korean biotech venture founded in 2009 that develops AI drug discovery platforms built on three-dimensional protein structure and genomic big data. Its main services include DeepMatcher hit-screening and lead-optimization tools, the NEO-ARS neoantigen screening service, the AB-ARS antibody discovery service, and the NGS-ARS genomic precision medicine service, which is provided to university hospitals in Korea. The company also runs its own drug pipeline and recently began a digital IR/PR solution business for biotech firms.
- What is the market cap of Synteka Bio?
- The market capitalisation of Synteka Bio was ₩26B at the close on Oct 29, 2026.
- Who are the largest shareholders of Synteka Bio?
- According to the latest official filings, the largest reported holders are Jeong Jong-seon (17.00%, as of Jul 29, 2026); Sangsangin Savings Bank (8.27%, as of Oct 12, 2026); Korea Investment Partners (1.61%, as of Aug 11, 2025).
- When is the next earnings report from Synteka Bio?
- Korean companies rarely announce results dates in advance. Based on when Synteka Bio filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
- Does the National Pension Service own Synteka Bio?
- Yes. The National Pension Service held 0.18% of Synteka Bio shares as of Dec 31, 2024.
Company profile
Shinteka Bio is a Korean biotech venture founded in 2009 that develops AI drug discovery platforms built on three-dimensional protein structure and genomic big data. Its main services include DeepMatcher hit-screening and lead-optimization tools, the NEO-ARS neoantigen screening service, the AB-ARS antibody discovery service, and the NGS-ARS genomic precision medicine service, which is provided to university hospitals in Korea. The company also runs its own drug pipeline and recently began a digital IR/PR solution business for biotech firms.
Written by AI from the company's latest annual report.
- Korean name
- 신테카바이오
- Sector
- Software
- CEO
- 정종선
- Founded
- Sep 2009
- Listed
- Dec 2019
- Listed shares
- 24,258,475
- Fiscal year ends
- Month 12
- Website
- www.syntekabio.com
Similar companies
- Hyundai Autoever307950 · ₩9.1T₩332,500−5.00%
- Krafton259960 · ₩8.3T₩181,000−1.20%
- NC036570 · ₩4.3T₩199,500−0.75%
- Netmarble251270 · ₩2.8T₩33,750+0.60%
- PearlAbyss263750 · ₩2.2T₩34,500+0.88%
- Shift UP462870 · ₩1.7T₩29,600+1.02%
- NHN181710 · ₩1.5T₩47,900−2.24%
- Kakao Games293490 · ₩1.2T₩11,210−2.18%
Recent news
Shinteka Biotech moves to set up management innovation committee, tightening fund controls and restructuring
Predicted impact: Medium
Management restructuring and fund controls at a small company after governance concerns.
[The Bell] Shintec Bio: "Improved new drugs and cancer vaccine candidates supplied directly to pharma companies"
Predicted impact: Low· Actual: −4.7% vs sector, volume 0.5× normal (5 trading days)
Shareholder meeting and holding report; routine governance notices for a small company.
Recent filings
See all- Results of Extraordinary Shareholders' MeetingOct 16, 2026
- Notice on Grant of Stock Purchase OptionsOct 16, 2026
- Determination of Shareholder Register Closure Period or Record DateOct 14, 2026
- Shareholders' meeting calledOct 14, 2026
- 5%+ holding reportOct 12, 2026
Titles in Korean until English translations are added.
Also known as: Synteka Bio / 신테카바이오 / 226330 / KRX:226330
Source: KRX statistical information